Presentations

Opioid Stewardship Across the Continuum of Care

Mary Lynn McPherson, PharmD, MA, MDE, BCPS; Tanya Uritsky, PharmD; Kelly Mendoza, MS, PharmD, BCPS

In the presentation “Opioid Stewardship Across the Continuum of Care”, Dr. McPherson, Dr. Uritsky and Dr. Mendoza describe ways to measure success in opioid stewardship across four practice arenas – outpatient, inpatient, palliative care, and hospice. Additionally, they discuss examples of best practices as part of opioid stewardship as well as recognizing/exposing the barriers to implementing opioid stewardship.

Handouts of Slides:

icoo.20.pp.0091 Opioid Stewardship Across the Continuum of Care Handouts

Clinical Pearls of Pharmacogenomics

Jeffrey Bettinger, PharmD, Pain Management Clinical Pharmacist, Saratoga Hospital Medical Group, Saratoga Springs, NY
Jacqueline Cleary, PharmD, BCACP, Assistant Professor of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, NY

The presentation will focus on the role of pharmacogenomic testing and result application in the setting of both acute and chronic pain management. Several pharmacodynamic and kinetic genes will be discussed as useful tools to better manage targeted pain therapies.

The field of pharmacogenomics is often viewed as the new frontier in pharmacology, as it quite literally combines pharmacology (the science of drugs) with genomics (the study of genes). Throughout the latter part of 21st century, research has continued to expand within this field not only in supporting the current use of pharmacogenomic testing in a variety of specialty areas, but identifying multiple genetic variants that can make an instrumental difference when managing pain.

Presentation Slide Handouts: icoo.20.pp.0111_Clinical pearls of pharmacogenomics – ICOO 2020 Handouts

Outreach, Intervention and Care Coordination for Patients with Opioid Use Disorder

Ari Kriegsman, MD; Erin Daley, RN, BSN; Carolyn Meuse, RN, BSN

We highlight one community hospital system’s efforts to combat the opioid crisis and help those most vulnerable to its effects. This includes street based outreach to engage those out of care, a hospital based addiction medicine service, residential treatment services, and care coordination to help navigate and give support throughout the continuum.

Presentation Handouts: icoo.20.pp.0046 3_2_KRIEGSMAN_DALEY_MEUSE_ICOO slide

Potentiating new Neurological pain drugs from cannabis (CBD/THC)

Sean Hall, MD
MedLab Clinical Limited
Alexandria, Australia

In this presentation, Dr. Hall discusses active research  identifying new neurological drugs based on  cannabis, specifically CBD/THC derived products for use in pain management.

Neurology is a complex area, potentially requiring a combination of surgical and non-surgical intervention. Regardless of the intervention plan, Neurology is hindered with a number of co-morbidities that can diminish patient outcomes, one in particular is pain. Pain management requires a number of pharmaceutical agents principally from the opioid class of drugs, potentiating heightened secondary organ toxicity profiles. Further it is accepted that some 33% + of patients undergoing chemotherapy will state that their pain is under-managed. Cannabinoids potentiate new treatments in pain management and posit opioid reduction.

Handouts of Slides:

Coming Soon.

Assessing Prevalence of Co-Occurring Mental Health Disorders in Non-Fatal Overdose Survivors

James Langabeer, PhD; Tiffany Champagne-Langabeer, PhD; Christine Bakos-Block, PhD; Andrea Yatsco, PhD
University of Texas Health Science Center at Houston

While it known there is a moderate co-occurrence of both psychiatric and opioid use disorder (OUD) generally, it is not known whether this significantly differs in a high risk population of those with a recent overdose. In this research, we focus on identifying the prevalence of co-occurring disorders, specifically for those non-treatment seeking individuals who access emergency services for opioid overdose.

TO SAVE A LIFE: EMERGENCY MEDICINE AND THE OPIOID EPIDEMIC

Tyler W. Barrett, MD MSCI FACEP FHRS, Associate Professor, Medical Director, Department of Emergency Medicine
Vanderbilt University Medical Center, Nashville, TN

Presentation Handouts: icoo.20.pp.0027_Barrett_2020_Sept_Presentation_EDandOpioids

Preliminary Results from a Post-Overdose Outreach & Emergency Department-Initiated Opioid Initiative

James Langabeer, PhD; Tiffany Champagne-Langabeer, PhD; Kimberly Chambers, MD
University of Texas Health Science Center at Houston

This study is funded by the Texas HHSC State Opioid Response Program, through SAMHSA. We know that treatment capacity alone is insufficient. We need better Coordination across medical, criminal justice, public health, and first responders. We may be at a critical juncture where patients are more ready and willing to engage in treatment.
Hypothesis: Immediate intervention, outreach, and comprehensive follow-up services initiated post-OD in the Emergency Department could be effective at improving engagement and retention in treatment. (Note: Please see a presentation from the same team located at: https://opioidconference.org/icoo-20-pp-0041/)

Presentation Slide Handouts: icoo.20.pp.0076 1_6_Intl Conf on Opioids Pres (Langabeers)

Cannibinoids: All the Rage, But Are They Safe and Effective?

Haley Busch, PharmD, BCPS
Clinical Pharmacist Specialist – Opioid Stewardship
CHI Saint Joseph Health

In this presentation, Dr. Busch discusses the legal status of cannabis and cannabis derived products for use in pain management. Additionally Dr. Busch presents the current literature available for potential utlization of cannabidiol in medical practice as well as reviewing the FDA approved cannabis-derived products and respective indications.

Handouts of Slides:

Coming Soon.

Unique Challenges in the Oncologic Pain Patients with Substance Use Disorders:
Scope of the Problem

Dhanalakshmi Koyyalagunta, MD; Joseph Arthur, MD; Larry Driver, MD

In this presentation, Dr. Koyyalagunta, Dr. Arthur and Dr. Driver explore the myriad unique challenges dealing with oncology patients with comorbid substance use disorders

Presentation Handouts:

icoo.20.pp.0036 1_2_1_KOYYALAGUNTA_ICOO 2019-LK_Slides

icoo.20.pp.0036 1_2_2_ARTHUR_ICOO 6.9.19_V2_slides

Opioid Induced Constipation in Chronic Pain

Velazquez Rivera, I.
Sanchez Del Aguila, M.
Garcia Velasco, M.P.

Unidad Del Dolor
Hospital De Alta Resolucion De Guadix, Spain

In this presentation, a Spanish team presents their latest findings on the management of opioid induced constipation for patients on opioid therapies.

Slide Handouts: icoo.20.pp.0021 opioid induced constipation – Guadix, Granada – SPAIN HANDOUT